ADTX · As filed with the SEC
Aditxt cash flow statement, by quarter
The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows (Unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 | Q2 2024† 3 months ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | (16,189,200) | (5,231,251)† | (24,207,669)† | (7,395,658)† | (5,952,465) | (5,547,172)† | (6,980,313)† | (7,623,879)† |
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Stock-based compensation | — | 0† | 0† | — | — | 4,369† | 32† | 4,097† |
| Stock-based compensation from asset purchase | — | 0† | 0† | 0† | 10,000 | 0† | 0† | 0† |
| Depreciation expense | 47,882 | 66,807† | 66,966† | 67,048† | 68,450 | 165,535† | 148,254† | 157,197† |
| Amortization of intangible assets | 834 | 833† | 833† | 834† | 833 | 833† | 834† | 833† |
| Amortization of debt discount - note payable | 24,687 | 60,000† | 234,167† | 1,212,246† | 200,284 | 272,965† | 1,709,537† | 556,708† |
| Amortization of debt discount - note receivable | — | (12,680)† | (108,112)† | — | — | — | — | — |
| Loss on note exchange agreement | — | — | — | — | — | 0† | 0† | 0† |
| Modifications of warrants as debt issuance costs | — | — | — | — | — | 0† | — | — |
| Modification of warrants for debt issuance costs | — | — | — | — | — | 0† | — | — |
| New principal from extension of notes, net of debt discount | — | — | — | — | — | 0† | 0† | 0† |
| Change in fair value of derivative liability | 11,800,798 | (228)† | (162)† | (980)† | (13,145) | — | — | — |
| Change in fair value of Evofem warrants | (25,004) | (358,413)† | (2,511,781)† | — | — | — | — | — |
| Impairment of Evofem F-1 preferred stock | — | 764,290† | — | — | — | — | — | — |
| Impairment of fixed assets | 32,275 | — | — | — | — | — | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (11,974) | 39,182† | 561† | 2,375† | 1,317 | 308,272† | 54,887† | 20,450† |
| Prepaid expenses | 294,310 | (554,746)† | 0† | 0† | (59,237) | 440,976† | (1,067)† | 13,596† |
| Deposits | — | 183,112† | (28,752)† | (36,100)† | (92,174) | 14,370† | 4,940† | 25,514† |
| Inventory | 9,289 | 798† | 1,045† | 1,440† | 2,188 | 77,749† | 476,507† | 57,267† |
| Accounts payable and accrued expenses | (562,609) | (4,012,540)† | 931,660† | 3,327,433† | (5,879,446) | (1,473,386)† | 1,446,190† | 3,778,341† |
| Settlement liability | — | — | — | — | — | 0† | (53,000)† | — |
| Net cash used in operating activities | (4,578,712) | (9,245,673)† | (2,344,554)† | (2,384,737)† | (11,713,395) | (6,146,990)† | (2,364,324)† | (2,289,876)† |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of fixed assets | (10,379) | — | — | — | — | — | — | — |
| Investment in Evofem F-1 preferred stock | — | — | — | — | — | (2,740,000)† | (1,260,000)† | — |
| Net cash used in investing activities | (10,379) | (13,743)† | 0† | — | — | (2,740,000)† | (1,260,000)† | — |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from notes payable, related party | — | 0† | 185,000† | — | — | 0† | 0† | 0† |
| Proceeds from notes and convertible notes payable, net of offering costs | 2,855,000 | (483,001)† | 170,000† | — | — | (50,000)† | 1,805,342† | 1,123,861† |
| Repayments of note payable - related party | — | — | — | — | — | — | — | 0† |
| Repayments of note payable, related party | — | (185,000)† | 0† | (493,000)† | (115,000) | (352,000)† | 0† | 0† |
| Repayments of note payable | (1,428,921) | (2,421,248)† | (265,874)† | (1,147,782)† | (2,778,978) | (2,957,379)† | (174,511)† | (250,000)† |
| New principal from extension of notes, net of debt discount | — | — | — | — | — | — | — | 0† |
| Common stock, preferred stock, and warrants issued for cash, net of issuance costs | 603,261 | 16,789,941† | 2,560,449† | 4,608,763† | 20,169,072 | 14,962,096† | 3,185,680† | — |
| Cash from subscription receivable | — | 149,027† | (149,027)† | 0† | 1,108,751 | 640,579† | (1,749,330)† | 0† |
| Proceeds from exercises of warrants | — | — | — | — | — | 0† | — | — |
| Redemptions of A-1 preferred stock | — | — | 0† | — | — | — | — | — |
| Redemptions of C-1 preferred stock | — | — | — | 0† | (7,027,065) | — | — | — |
| Redemptions of A-1 preferred stock | (369,996) | — | — | — | — | — | — | — |
| Net cash provided by financing activities | 1,659,344 | 12,294,974† | 2,183,916† | 4,657,000† | 11,356,780 | 9,391,425† | 3,861,697† | 3,292,428† |
| NET DECREASE IN CASH | (2,929,747) | — | — | (152,737)† | (356,615) | 504,435† | 237,373† | 2,552† |
| CASH AT BEGINNING OF PERIOD | 3,198,599 | 163,041 | 323,679 | 476,416 | 833,031 | 358,596 | 91,223 | 88,671 |
| CASH AT END OF PERIOD | 268,852 | 3,198,599 | 163,041 | 323,679 | 476,416 | 833,031 | 328,596 | 91,223 |
| Supplemental cash flow information: | ||||||||
| Cash paid for interest | 152,965 | 1,201,042† | 0† | 0† | 1,264,504 | 612,878† | 0† | 0† |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Issuance of shares for the conversion of notes payable | — | — | — | — | — | 0† | 0† | — |
| Debt discount from shares issued as inducement for note payable | — | — | — | — | — | 0† | 913,713† | — |
| Debt discount from shares issued as inducement for note payable | — | — | — | — | — | 0† | 913,713† | — |
| Warrant modification | — | — | — | — | — | 0† | 5,902,874† | — |
| Issuance of shares in asset purchase | — | — | — | — | — | 0† | 0† | — |
| Shares issued for settlement | — | — | — | — | — | 0† | 0† | 0† |
| Shares issued for settlement | — | — | — | — | — | 0† | 1,440,000† | (106,448)† |
| Return of notes payable from Evofem merger agreement | — | — | — | — | — | 180† | 0† | 0† |
| Accrued interest rolled into notes payable | — | 0† | — | — | — | 0† | (45,000)† | 0† |
| Derivative liability from conversion feature on warrants | 13,736,777 | — | — | — | — | — | — | — |
| Derivative liability from conversion feature on preferred stock | 9,913,157 | — | — | — | — | 0† | (10,745,228)† | (180)† |
| ELOC payable | — | 0† | (302,034)† | 0† | 630,105 | — | — | — |
| Series C-1 redemption payable | — | (843,011)† | (1,521,536)† | 1,354,678† | 1,247,267 | — | — | — |
| Series C-1 Deemed Dividend | — | — | — | — | 1,354,774 | — | — | — |
| ELOC commitment fee stock payable | — | 0† | 0† | 0† | 2,250,000 | — | — | — |
| Loan in escrow | — | 0† | 0† | — | — | — | — | — |
| Reclassification of series A-1 preferred shares to liabilities | 369,996 | (561,603)† | 561,603† | — | — | — | — | — |
| Conversion of Series A-1 to common stock | 20,000,000 | — | — | — | — | 5,333,000† | 167,000† | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.